Abstract
The effect of the novel aromatic bisamidine 1 on protein synthesis in cell-free translational system isolated from rat livers was studied. The bisamidine 1 caused inhibition of [14C]leucine incorporation into proteins proportionally to its concentration. To establish a precise mechanism of inhibition, we evaluated the effect of the bisamidine 1 on the isolated ribosomes and purified to homogeneity elongation factors. Preincubation of the bisamidine 1 with ribosomes resulted in partial inhibition of their activity in whole elongation system. The eucaryotic elongation factor 1 (eEF-1) was not significantly affected by the bisamidine 1. In contrast to eEF-1, the bisamidine 1 preincubated with the eucaryotic elongation factor 2 (eEF-2) caused total inhibition of its activity in the translocation process. The inhibitory effect of the bisamidine 1 on eEF-2 activity was confirmed in diphtheria toxin-dependent ADP-ribosylation reaction. The results suggest a high action specificity of the bisamidine 1 as potential anticancer drug, since the primary target seems to be highly conserved protein-elongation factor 2.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bailly Ch, Dassonneville L, Carrasco C, Lucas D, Kumar A, Boykin DW, Wilson WD: Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives. Anti-Cancer Drug Des 14: 47–60, 1999
Denny WA: New direction in the design of anticancer drugs. Drug Des Delivery 3: 99–124, 1988
Boykin DW, Kumar A, Spychala J, Zhou M, Lombardy RJ, Wilson WD, Dykstra ChC, Jones SK, Hall JE, Tidwell RR, Laughton Ch, Nunn ChM, Neidle S: Dicationic diarylfurans as anti-Pneumocystis carinii agents. J Med Chem 38: 912–916, 1995
Gambari R, Nastruzzi C: DNA-binding activity and biological effects of aromatic polyamides. Biochem Pharmacol 47: 599–610, 1994
Chiang SAY, Welch J, Rauscher FJ, Beerman TA: Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Biochemistry 33: 7033–7040, 1994
Bailly Ch, Chaires JB: Sequence-specific DNA minor groove binders. Design and synthesis of netropsin and distamycin analogues. Bioconjugate Chem 9: 513–538, 1998
Neidle S, Kelland LR, Trent JO, Simpson IJ, Boykin DW, Kumar A, Wilson WD: Cytotoxicity of bis(phenylamidinium)furan alkyl derivatives in human tumour cell lines: Relation to DNA minor groove binding. Bioorg Med Chem Lett 11: 1403–1408, 1997
Moldave K: Eukaryotic protein synthesis. Annu Rev Biochem 54: 1109–1149, 1985
Riis B, Rattan SIS, Clark BFC, Merrick WC: Eukaryotic protein elongation factors. Trends Biochem Sci 15: 420–424, 1990
Gajko A, Galasinski W, Gindzienski A: Purification and characterization of the protein kinase eEF-2 isolated from rat liver cells. Acta Biochim Polon 41: 421–427, 1994
Nygard O, Nilsson A, Carlberg U, Nilsson L, Amons R: Phosphorylation regulates the activity of the eEF-2 specific Ca2+ and calmodulin-dependent protein kinase III. J Biol Chem 266: 16425–16430, 1991
Lee H, Iglewski WJ: Cellular ADP-ribosyltransferase with the same mechanism of action as diphtheria toxin and Pseudomonas toxin A. Proc Natl Acad Sci USA 81: 2703–2707, 1984
Iglewski BH, Liu P, Kabat D: Mechanism of action of Pseudomonas aeruginosa exotoxin A: Adenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect Immun 15: 138–144, 1997
Bielawski K, Galicka A, Bielawska A, Sredzinska K: Inhibitory effects of pentamidine analogues on protein biosynthesis in vitro. Acta Biochim Polon 47: 113–120, 2000
Skogerson L, Moldave K: The binding of aminoacyl transferase II to ribosomes. Biochem Biophys Res Commun 27: 568–572, 1967
Galasinski W, Moldave K: Purification of aminoacyltransferase II (translocation factor) from rat liver. J Biol Chem 244: 6527–6532, 1969
Moldave K: The preparation of 14C-amino acyl soluble-tRNA. Meth Enzymol 6: 757–761, 1963
Gajko A, Galasinski W, Gindzienski A: Multiformity of elongation factor eEF-2 isolated from rat liver cells. Biochem Biophys Res Commun 202: 844–849, 1994
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.) 227: 680–685, 1970
Riis B, Rattan SIS, Clark BFC: Estimating the amounts of ADPribosylatable active elongation factor-2 in mammalian cell-free extracts. J Biochem Biophys Meth 19: 319–326, 1989
Laskey RA, Mills AD: Quantitative film detection of 3H and 14C in polyacrylamide gels by fluorography. Eur J Biochem 56: 335–341, 1975
Gajko A, Sredzinska K, Galasinski W, Gindzienski A: Possibility of the transformation of eEF-2 (100 kDa) to eEF-2 (65 kDa) in the peptide elongation process in vitro. Biochem Biophys Res Commun 255: 535–538, 1999
Galicka A, Sredzinska K, Gindzienski A: Cytoplasmic inhibitor of eEF-2 ADP-ribosylation catalyzed by diphtheria toxin or endogenous transferase in rat liver cells. Biochem Biophys Res Commun 269: 553–556, 2000
Nilsson L, Nygard O: Localization of the sites of ADP-ribosylation and GTP binding in the eukaryotic elongation factor EF-2. Eur J Biochem 148: 299–304, 1985
Nygard O, Nilsson L: Characterization of the ribosomal properties required for formation of a GTPase active complex with the eukaryotic elongation factor 2. Eur J Biochem 179: 603–608, 1989
Rights and permissions
About this article
Cite this article
Gajko-Galicka, A., Bielawski, K., Sredzinska, K. et al. Elongation factor 2 as a target for selective inhibition of protein synthesis in vitro by the novel aromatic biasamidine. Mol Cell Biochem 233, 159–164 (2002). https://doi.org/10.1023/A:1015548131930
Issue Date:
DOI: https://doi.org/10.1023/A:1015548131930